Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, Caprion Extend Cancer Antibody Partnership

NEW YORK (GenomeWeb News) — Abbott today said it has extended a research partnership with Caprion Proteomics to identify and use cancer antibody targets.
The agreement grants Abbott exclusive rights for up to two years to 10 lung cancer targets that Caprion found.
The new agreement extends an alliance the companies struck three years ago in which Abbott and Caprion used Caprion’s CellCarta proteomics platform to evaluate cell-surface drug targets by comparing plasma membrane proteins in normal tissues and cancer tissues.
Specific financial terms of the agreement were not released.
“From day one, the partnership with Caprion has resulted in a series of potential therapeutic antibody targets,” said Abbott divisional vice president Stephen Fesik said in a statement.
The new agreement will grant more time to wrap up pre-clinical evaluation of the 10 targets Abbott chose, Fesik added.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.